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Should colorectal cancer screening start at the same age in
European countries? Contributions from descriptive epidemiology
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We assessed incidence and mortality of colorectal cancer (CRC) at various ages among women and men in 38 European countries.
The ages at which defined levels of incidence and mortality were reached varied between 9 and 17 years between countries.
This variation requires consideration in the definition of screening guidelines.
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Colorectal cancer (CRC) is the third most common cancer and the
fourth most common cancer cause of death globally (Parkin et al,
2005). In Europe, more than 400000 new cases and more than
200000 deaths occur per year (Ferlay et al, 2007). On account
of its typically slow development, there is a large potential to
reduce the burden of the disease by early detection and removal of
precancerous lesions or early cancer stages. Various screening
examinations, including fecal occult blood testing, sigmoidoscopy
and colonoscopy have meanwhile been recommended by expert
committees (eg Europe Against Colorectal Cancer, 2007), and
nationwide screening programmes are currently being implemen-
ted, prepared or under consideration in different European
countries. Within the European Union, recommendations on
cancer screening typically foresee a defined common starting age
(eg Advisory Committee on Cancer Prevention, 2000). However,
CRC incidence and mortality strongly vary within Europe. The aim
of this study was to assess differences in CRC incidence and
mortality within Europe, in view of the potential implications
regarding variation of age at screening initiation between
countries.
MATERIALS AND METHODS
Analytic strategy
Our analyses are based on the following strategy: We looked
at median CRC incidence and mortality among men across Europe
at ages 50, 55 and 60, and we determined at what ages these levels
of incidence and mortality are reached among men and women
in each country. The rationale behind this ‘risk advancement
approach’ (Brenner et al, 1993) is as follows: CRC incidence and
mortality strongly increase with age. The age at which CRC
screening becomes meaningful and cost effective depends, among
other factors, on CRC incidence and mortality surpassing some
minimum threshold in the absence of screening. This threshold,
however defined, is reached at various ages in different countries.
All of the aforementioned ages have been recommended or are
actually used in practise for initiation of CRC screening (Advisory
Committee on Cancer Prevention, 2000; Malila et al, 2005; Pox
et al, 2007; West et al, 2007).
Database
Estimates of CRC incidence and mortality rates for age groups
15–44, 45–54, 55–64, and 65þ years were obtained for 38
European countries from the GLOBOCAN 2002 database (Ferlay
et al, 2004).
Statistical analyses
In our analyses, we made the following approximations: CRC
incidence and mortality at age 40 years were approximated as
0.75 3¼2.25 times the corresponding rates in the 30-year
interval 15–44 years. This approximation is based on the
observation that roughly 75% of CRC cases diagnosed in the age
range 15–44 years occur in the age interval 35–44 years in
populations where more detailed age-specific rates are available,
and on the assumption that age interval 35–44 years typically
comprises roughly one-third of the population in age interval
15–44 years. CRC incidence and mortality at ages 50 and 60 were
assumed to equal the corresponding rates in age groups 45–54 and
55–64 years, respectively. Finally, it was assumed that data on
CRC incidence and mortality in men and women in age group
65þ years correspond to the respective levels at the mean age of
the male and female population aged 65þ years in each country in
the year 2000, which was derived from the United Nations
Population Database (United Nations Population Division, 2007).
Based on the assumptions described above, defined levels of
CRC incidence and mortality were available for ages 40, 50, 60,
and for an age between 72 and 75 years (men) or between 73 and
77 years (women), respectively, with the latter varying across
Received 9 May 2008; revised 2 June 2008; accepted 9 June 2008;
published online 15 July 2008
*Correspondence: Professor H Brenner;
E-mail: h.brenner@dkfz-heidelberg.de
British Journal of Cancer (2008) 99, 532–535
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.com
E
p
i
d
e
m
i
o
l
o
g
ycountries. Incidence and mortality at single years of age between
these defined levels were approximated by linear interpolation.
Sensitivity analyses varying the aforementioned approximations
within plausible ranges led only to very minor variation of the
results and are therefore not shown in detail.
RESULTS
CRC incidence strongly increased with age in all countries.
Estimates of median incidence (mi) across countries among men
aged 50, 55 and 60 years were 37, 73, and 112 per 100000 persons
per year, respectively. The age at which these levels were reached
among men and women in the different countries, denoted agemi50,
agemi55, and agemi60, respectively, varied strongly. For example,
among men, agemi50 varied between 45 years in Hungary and
55 years in Greece (see Table 1). Similarly, agemi55, and agemi60
varied between 51 and 62 years, and 54 and 67 years among men
in the same countries. As illustrated in Figure 1, this is explained
by the much steeper rise in CRC incidence with age in Hungarian
men compared with Greek men. Overall, among men in Western
Europe, incidence rates were higher, and the various levels of
incidence were reached at younger ages compared with men from
other European regions. However, there was also substantial
variation within regions.
Among women, incidence rates were generally lower compared
with men, which implies that specified levels of incidence were
reached at higher ages. With few exceptions, between-country
variation was similar among women and men, but it was
particularly large among older women, reaching a maximum of
17 years (from 60 to 77 years) for agemi60.
CRC mortality likewise strongly increased with age in all
countries. Estimates of median mortality (mm) across countries
among men aged 50, 55 and 60 years were 14, 33, and 52 per
100000 persons per year, respectively. The age at which these
levels were reached among men and women in the different
countries, denoted agemm50, agemm55, and agemm60, respectively,
again showed strong between-country variation. The lowest and
highest levels of these ages (resulting from highest and lowest
levels of mortality) were again mostly seen for Hungary and
Greece, respectively (see Table 2 and Figure 2). Agemm50, agemm55,
and agemm60 varied up to 12 years between countries among both
women and men. Again, these ages tended to be higher among
women (ranges across countries: 45–57, 54–64, and 60–69 years,
respectively) than among men (ranges across countries: 43–54,
51–62, and 53–65 years, respectively). In Eastern countries,
mortality was generally higher, and levels of agemm50, agemm55, and
agemm60 were generally lower than in countries from other parts of
Europe.
Table 1 Age at which colorectal cancer incidence among men and
women in European regions and countries reaches median values across
countries for men at ages 50, 55, and 60 years (agemi50, agemi55, agemi60)
Men Women
Region Country agemi50 agemi55 agemi60 agemi50 agemi55 agemi60
East Belarus 51 57 62 52 62 71
Bulgaria 51 57 63 55 64 72
Czech Republic 45 51 k 54 k 50 55 61
Hungary 45 k 51 54 48 k 55 61
Moldova 48 55 62 52 61 75
Poland 51 55 60 52 59 65
Romania 52 59 66 56 67 m 77 m
Russian Fed. 51 56 61 52 60 71
Slovakia 46 51 54 50 57 63
Ukraine 51 56 61 52 63 77
North Denmark 50 55 60 50 57 62
Estonia 52 57 61 53 60 65
Finland 53 60 64 54 62 68
Iceland 51 57 61 52 57 63
Ireland 49 53 58 52 59 64
Latvia 50 60 64 54 63 71
Lithuania 52 57 62 55 64 72
N o r w a y 4 95 45 84 854 k 60 k
Sweden 51 57 61 52 59 64
United Kingdom 50 54 59 52 60 64
South Albania 50 56 62 51 62 72
Bosnia/Herzegovina 49 54 59 51 60 67
Croatia 47 53 57 50 58 64
Greece 55 m 62 m 67 m 58 m 65 72
Italy 48 54 59 49 58 64
Macedonia 51 57 62 53 62 69
Malta 51 58 63 49 61 67
Portugal 50 54 59 52 61 67
Slovenia 48 53 56 51 58 64
Spain 49 54 60 52 61 66
Serbia/Montenegro 50 56 61 51 62 71
West Austria 49 54 58 52 59 64
Belgium 51 55 60 52 59 64
France 48 54 58 51 59 65
Germany 46 52 57 49 57 62
Luxembourg 47 53 57 51 59 63
Netherlands 49 54 58 50 56 62
Switzerland 49 53 57 51 60 65
Lowest (k) and highest (m) ages in each column are marked bold.
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Figure 1 Age-specific incidence of colorectal cancer among men (solid
lines) and women (dashed lines) in Hungary (black lines) and Greece (grey
lines). The vertical lines indicate the median incidence across European
countries among men aged 50 (mi50), 55 (mi55) and 60 years (mi60),
respectively.
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Our comparative analyses of age- and sex-specific CRC incidence
and mortality in 38 European countries indicate that differences in
incidence and mortality between countries translate to wide age
ranges at which comparable levels of risk are reached. Age-specific
CRC incidence and mortality represent important parameters
regarding potential benefits of screening, which have to be weighed
against costs and potential adverse side effects when choosing the
age at screening initiation. Our analyses suggest that the balance in
favour of screening is likely to be reached at rather different ages
in the various European countries.
The reasons for this variation are likely to be manifold.
Differences in risk factor profiles, such as dietary habits, across
European countries, may be most relevant for variation in CRC
incidence. As regards mortality, major differences in survival of
CRC patients between European countries also play an important
role (Verdecchia et al, 2007).
Even though CRC incidence and mortality data are important,
there are further, country-specific factors to be considered in
the choice of the age range at which screening is offered.
For example, an important parameter is remaining life
expectancy (Ko and Sonnenberg, 2005). Furthermore, non-
epidemiological criteria, such as the availability and costs of
various screening modalities in different countries have to be
taken into account.
Risk adapted variation of ages for CRC screening initiation is
already well accepted and established for CRC risk factors other
than ‘country’, in particular a family history of CRC (Europe
Against Colorectal Cancer, 2007). The ‘risk advancement’ (Brenner
et al, 1993) given a positive family history is of similar magnitude
than the between country differences of up to 10 years or more
observed in the present analyses (Brenner et al, 2008). As regards
gender differences, risk advancement among men compared to
women is roughly 5 years (Brenner et al, 2007). Taken together,
these patterns suggest that appropriate differentiation of age at
initiation of CRC screening by gender and country might be
similarly or even more relevant from a public health point of view
than the widely practised differentiation by family history, an
important but relatively infrequent CRC risk factor.
Table 2 Age at which colorectal cancer mortality among men and women in European regions and countries reaches median values across countries for
men at ages 50, 55, and 60 years (agemm50, agemm55, agemm60)
Men Women
Region Country agemm50 agemm55 agemm60 agemm50 agemm55 agemm60
East Belarus 49 54 58 50 59 64
Bulgaria 47 54 60 50 60 65
Czech Republic 44 51 53 48 56 61
Hungary 43 k 51 k 53 k 46 54 k 60 k
Moldova 45 53 58 50 58 66
Poland 50 55 59 52 60 64
Romania 50 57 62 52 62 68
Russian Fed. 49 54 58 50 56 61
Slovakia 45 51 53 49 56 61
Ukraine 48 53 57 50 57 64
North Denmark 48 54 59 48 58 61
Estonia 51 55 60 51 58 63
Finland 53 61 64 54 63 67
Iceland 54 60 62 53 60 63
Ireland 45 52 56 51 60 63
Latvia 47 55 61 52 60 63
Lithuania 50 55 59 52 60 64
Norway 50 57 61 50 58 62
Sweden 52 59 62 54 62 65
United Kingdom 50 56 61 53 61 64
South Albania 50 55 60 51 60 65
Bosnia/Herzegovina 49 54 58 51 59 63
Croatia 48 53 56 51 58 62
Greece 54 m 62 m 65 m 57 m 64 m 69 m
Italy 50 57 61 53 62 65
Macedonia 51 59 63 53 63 68
Malta 52 55 58 45 k 57 64
Portugal 50 55 60 52 61 64
Slovenia 47 53 56 50 60 63
Spain 49 56 61 52 61 65
Serbia/Montenegro 49 54 59 50 59 64
West Austria 50 55 60 52 60 63
Belgium 51 56 61 52 60 63
France 51 57 61 53 61 65
Germany 50 55 60 52 60 62
Luxembourg 51 56 61 54 61 64
Netherlands 50 56 60 51 60 63
Switzerland 52 58 62 55 62 66
Lowest (k) and highest (m) ages in each column are marked bold.
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should be kept in mind. Our analyses are based on data on CRC
incidence and mortality by age and sex. Additional factors, such as
potential variation in screening effectiveness by age, for which data
are lacking, were not considered. In some of the countries included
in this analysis, some form of CRC screening has already been
practised before 2002, but, because of mostly small regional
coverage (Benson et al, 2008) it is unlikely to have had a major
effect on CRC incidence and mortality on the national level.
Although estimates on CRC incidence and mortality in 2002
obtained from GLOBOCAN 2002 are based on the best available
data sources, they are subject to uncertainties due to lack of or
incomplete population coverage of cancer registration in many
countries.
Analyses were presented in detail for selected ‘threshold
levels’ of incidence and mortality only. Latter were defined
by median levels across countries among men at ages 50, 55 and
60 years, which may not necessarily be the best ‘threshold
levels’. Best threshold levels and optimum age for commencing
screening will be based on cost-benefit decisions. However, as can
be seen from Figures 1 and 2, differences in ages at which
thresholds are reached would be rather similar for any other
intermediate levels of incidence and mortality within the assessed
range.
In summary, our analyses do not allow deriving a general
recommendation regarding the best age for initiation of CRC
screening in each country. Our results do suggest, however, that
the optimal age for screening initiation is likely not to be the same
for European countries and that variation by up to 10 years or even
more across countries might be warranted because of major
differences in CRC incidence and mortality.
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Figure 2 Age-specific mortality of colorectal cancer among men (solid
lines) and women (dashed lines) in Hungary (black lines) and Greece (grey
lines). The vertical lines indicate the median mortality across European
countries among men aged 50 (mm50), 55 (mm55) and 60 years (mm60),
respectively.
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